Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply

Vaccine. 2020 Jul 22;38(34):5418-5423. doi: 10.1016/j.vaccine.2020.06.022. Epub 2020 Jun 11.

Abstract

The World Health Organization declared the COVID-19 disease as a pandemic requiring a rapid response. Through online search, direct communication with network members and an internal survey, engagements of developing countries' vaccine manufacturers' network members in the research and development of COVID-19 vaccines and their capacities in the manufacturing, fill-finish and distribution of vaccines were assessed. Currently, 19 network members engaged in research and development of COVID-19 vaccines, using six principal technology platforms. In addition, an internal survey showed that the number of vaccines supplied collectively by 37 members, in 2018-19, was about 3.5 billion doses annually. Almost a third of network members having vaccines prequalified by the World Health Organization comply with international regulations and mechanisms to distribute vaccines across borders. The use of existing manufacturing, fill-finish and distribution capabilities can support an efficient roll-out of vaccines against COVID-19, while maintaining supply security of existing vaccines for on-going immunization programmes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomedical Research / organization & administration*
  • COVID-19
  • COVID-19 Vaccines
  • Clinical Trials as Topic
  • Coronavirus Infections* / immunology
  • Coronavirus Infections* / prevention & control
  • Drug Industry / organization & administration*
  • Humans
  • International Cooperation*
  • Pandemics* / prevention & control
  • Pneumonia, Viral* / prevention & control
  • Viral Vaccines / immunology
  • Viral Vaccines / supply & distribution*
  • World Health Organization

Substances

  • COVID-19 Vaccines
  • Viral Vaccines